Issa, G. C., Cuglievan, B., Hajjar, G. E., Jen, W. Y., Bataller, A., Short, N. J., DiNardo, C. D., Alvarado, Y., Loghavi, S., Duose, D. Y., Zhang, B., Furudate, K., Ning, J., Xiao, L., Mouhayar, E., Pinto, A., Bidikian, A., Thompson, E., Daver, N., Garcia-Manero, G., Farhat, A., McCall, D., Kadia, T. M., Abbas, H. A., Tan, S., Bazinet, A., Jabbour, E., Montalban-Bravo, G., Ravandi, F., Takahashi, K., Andreeff, M., Kantarjian, H. M. (2026). Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE). Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-01743